Clinical Trials

77 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT01239342 2019-10-10

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

43 enrolled 12 charts

Genitourinary

Carcinoma, Renal Cell

NCT01802320 2019-09-20

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

18 enrolled 7 charts

Colonic Neoplasms, Rectal Neoplasms

NCT01604772 2019-05-01

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

16 enrolled 7 charts

Head & Neck

Salivary Gland Neoplasms

NCT00670488 2019-04-01

MK-2206-002

104 enrolled 28 charts

Tumor-Agnostic

Neoplasms

NCT01277757 2018-12-19

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

30 enrolled 7 charts

Breast Neoplasms

NCT01253447 2018-08-27

AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Other hematologic neoplasm

19 enrolled 8 charts

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT01021748 2018-08-07

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

63 enrolled 17 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT01344031 2018-07-23

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

31 enrolled

Breast Neoplasms

NCT01776008 2018-05-08

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

16 enrolled 5 charts

Breast Neoplasms

NCT01349933 2017-12-05

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

21 enrolled 11 charts

Head & Neck

Recurrent Squamous Cell Carcinoma of the Nasopharynx

NCT01481129 2017-09-28

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

LymphoidOther hematologic neoplasm

22 enrolled 9 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01369849 2017-09-15

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1/2 Completed

15 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01319539 2017-08-30

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

12 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01263145 2017-08-25

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

34 enrolled

Breast Neoplasms

NCT01783171 2017-08-22

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

42 enrolled

Pancreatic Neoplasms

NCT01370070 2017-01-13

MC1079

12 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT01294306 2016-11-29

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

80 enrolled 10 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT01283035 2016-06-24

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

6 enrolled 7 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01425879 2016-06-17

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

8 enrolled 8 charts

Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01249105 2016-03-10

MK-2206 for Recurrent Malignant Glioma

Phase 2 Withdrawn

CNS

Glioma

NCT01658943 2016-03-09

S1115

137 enrolled 12 charts

Pancreatic Neoplasms

NCT01169649 2016-02-18

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

11 enrolled 6 charts

EndocrineNET

Neuroendocrine Tumors

NCT01260701 2016-01-18

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

75 enrolled 9 charts

Stomach Neoplasms

NCT01186705 2015-11-18

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

1 enrolled 4 charts

Colonic Neoplasms, Rectal Neoplasms

NCT01239355 2015-10-05

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

15 enrolled 6 charts

Carcinoma, Hepatocellular

NCT01333475 2015-09-30

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

21 enrolled 11 charts

Colorectal Neoplasms

NCT01071018 2015-09-07

A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)

24 enrolled

Other solid neoplasm

Solid Tumors

NCT01281163 2015-08-27

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Phase 1 Terminated

4 enrolled

Breast Neoplasms

NCT01295632 2015-08-27

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

65 enrolled

BreastCNSGynecologic

Breast Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT01245205 2014-10-23

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

28 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 2 Withdrawn

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01466868 2014-07-10

AKTIL

22 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

2 enrolled 9 charts

Dermatologic

Melanoma

NCT01231919 2014-04-29

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

LymphoidMyeloidOther hematologic neoplasmSarcoma

45 enrolled

Myeloproliferative Syndrome, Transient, Pdgfra-Associated Chronic Eosinophilic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blast Crisis, Burkitt Lymphoma, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT01235897 2014-04-17

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

17 enrolled 7 charts

Tumor-Agnostic

Neoplasms

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1 Terminated

60 enrolled

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

NCT01240941 2013-08-20

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Phase 2 Withdrawn